Clinicopathological Characteristics and Prognostic Factors of Synchronous Endometrial and Ovarian Cancers—A Single-Institute Review of 43 Cases

Jain, Vandana; Sekhon, Rupinder; Pasricha, Sunil; Giri, Shveta; Modi, Kanika Batra; Shrestha, Eliza; Ram, Dharma; Rawal, Sudhir

doi:10.1097/igc.0000000000000971

Cited by 23 publications

(25 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective study in Japan, 2 of 23 patients with synchronous EC and OC experienced recurrence after adjuvant therapy, though none of 10 patients who did not receive adjuvant therapy had recurrence [23]. Studies on high-risk factors of recurrence may provide an index or indications for adjuvant therapy [24, 25]. Interestingly, concordant tumor grade was not associated with survival for stage I synchronous carcinomas in a large case–control study [10].…”

Section: Discussionmentioning

confidence: 99%

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas

Zhan

et al. 2019

Arch Gynecol Obstet

View full text Add to dashboard Cite

Introduction Little is known about the prevalence and prognosis of synchronous endometrial and ovarian carcinomas. This report explores the survival outcomes of synchronous stage IA endometrioid endometrial and stage IA ovarian carcinomas in a retrospective cohort study. Methods All cases of pathological confirmed synchronous stage IA endometrial endometrioid and ovarian carcinomas from June 1, 2010, to June 1, 2017, in a teaching hospital were reviewed. Patients were followed up to February 1, 2019. Survival outcomes were compared between patients with and without synchronous carcinomas. Results In total, 841 cases with confirmed FIGO stage IA endometrioid endometrial carcinomas were included in the study; 33 patients (3.9%) had synchronous stage IA ovarian carcinomas, including 27 (81.8%) and 6 (18.2%) cases of endometrioid and mixed endometrioid/clear cell subtypes, respectively. After a median follow-up time of 56.8 months, 829 patients (97.9%) had definitive survival outcomes. Synchronous ovarian carcinomas had no impact on disease-free, overall or cancer-specific overall survival in univariate and multivariate analyses. Conclusion In these patients with stage IA endometrioid endometrial carcinoma, the genuine incidence of synchronous stage IA ovarian carcinoma was very low, and synchronous carcinoma had no significant effects on survival outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas

Zhan

et al. 2019

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…It may be due to small sample size and high frequency of endometrioid endometrial and ovarian double primary cancer. This synchronous or metachronous endometrial and ovarian cancer is known to show endometrioid histological type in more than 50%–80% cases [ 34 35 36 ]. We had 7.0% (9/129 cases) of synchronous or metachronous endometrial and ovarian cancer in this research and it is similar to previous report that synchronous endometrial and ovarian cancer is account for 10% of all ovarian cancer patients [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer

et al. 2018

View full text Add to dashboard Cite

ObjectiveLynch syndrome is a cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes. Lynch syndrome only causes about 0.4% of cases of ovarian cancer, which suggests that universal screening may not be cost-efficient. However, the frequency of Lynch syndrome in ovarian cancer is unclear in the Asian population. The goal of the study was to investigate a screening strategy using family history.MethodsThe subjects were 129 patients with ovarian cancer. Clinical and family history were collected using a self-administered questionnaire, and Society of Gynecologic Oncology (SGO) criteria 2007 and PREMM5 were used for risk assessment. Microsatellite instability, immunohistochemistry, and methylation of MMR genes were analyzed.ResultsOf the 129 cases, 25 (19.4%) met the SGO criteria, and 4 of these 25 had MSI-high and MMR deficiency. Two cases had loss of MSH2 and MSH6, indicating MSH2 mutation, and the other two had loss of MLH1 and PMS2, including one without MLH1 methylation indicating MLH1 mutation. These results show that screening using family history can detect Lynch syndrome in 12.0% (3/25) of ovarian cancer cases. The 3 cases were positive for PREMM5, but negative for Amsterdam II criteria and revised Bethesda guidelines. Genetic testing in one case with MSH2 and MSH6 deficiency confirmed the diagnosis of Lynch syndrome with MSH2 mutation.ConclusionThis is the first study of screening for Lynch syndrome in ovarian cancer using clinical and family history in an Asian population. This approach may be effective for diagnosis in these patients.

show abstract

“…In 1998, Scully proposed more detailed diagnostic criteria. Since the above criteria are widely used, there are many studies comparing the characteristics and prognoses in these two groups (MC and DPC) [4][5][6][7][8][9][10][11][12][13][14][15]. A prior study suggested that the prognosis was poor when metastasis involved other sites in addition to the uterus and ovaries and when there was no distinction between the DPC and MC [5].…”

Section: Introductionmentioning

confidence: 99%

“…Early-stage DPC showed a good prognosis in a study conducted only on DPC patients [10]. Song et al showed the association of the initial CA-125 level and ovarian stage with DPC survival [11], while Jain et al showed the association between lymphovascular invasion and DPC survival [12]. When comparing DPC with endometrial cancer, prognosis is not inferior than that in endometrial cancer [13].…”

Section: Introductionmentioning

confidence: 99%

How to Manage Synchronous Endometrial and Ovarian Cancer Patients?

Shin

Park

Kang

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: We aimed to evaluate the prognosis in patients with synchronous endometrial and ovarian cancer (SEOC) by comparing the differences between double primary cancer (DPC) and metastatic cancer (MC). Methods: The medical records of 47 patients diagnosed synchronously with endometrial and ovarian cancer between January 2006 and December 2018 were retrospectively reviewed. Twenty-eight and 19 patients were diagnosed with DPC and MC, respectively. Demographics, recurrence-free survival (RFS), and 5-year overall survival (OS) were compared. The clinical factors affecting survival were evaluated using univariate and multivariate analyses.Results: The demographics were not different between both groups. Endometrioid histology and the International Federation of Gynecology and Obstetrics grade were higher in the MC group than in the DPC group (42.1% vs. 10.7 %; P=0.018, P=0.002, respectively). The ratio of post-operative adjuvant therapy was not different in both groups. Recurrence occurred in five patients with DPC and seven with MC. The difference in RFS was not significantly different (P=0.131) but the OS was different between both groups (P = 0.020). Histology and para-aortic lymph node metastasis were associated wtih RFS in univariate analysis, but no difference was found in multivariate analysis.Conclusions: Although DPC patients had longer OS, multivariate analysis did not identify any influential factors. Focus should be placed on defining the appropriate adjuvant treatment for high-risk patients, which will improve prognosis, rather than on discriminating between DPC and MC.

show abstract

Clinicopathological Characteristics and Prognostic Factors of Synchronous Endometrial and Ovarian Cancers—A Single-Institute Review of 43 Cases

Cited by 23 publications

References 23 publications

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas

Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer

How to Manage Synchronous Endometrial and Ovarian Cancer Patients?

Contact Info

Product

Resources

About